BC Partners Falls Short of Target in Private Equity Fund Raise

A widening valuation gap is leaving otherwise healthy companies stranded in aging private-equity portfolios.

As GP-led secondaries scale to record levels, top investors are flagging a widening gap between trophy assets and weaker deals, even as new financing tools like CFOs further blur the line between sale and securitization.

The divestiture is a key component of IFF’s portfolio transformation strategy and will further concentrate the company on its Taste, Scent and Health & Biosciences segments.